Severe Hemophilia A Clinical Trials in Guangzhou
3 recruitingGuangzhou, China
Showing 1–3 of 3 trials
Recruiting
Phase 3
Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.
Severe Hemophilia A
Hangzhou Gensciences Biopharmaceutical Co., Ltd.60 enrolled19 locationsNCT07684898
Recruiting
Phase 3
Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment
Severe Hemophilia A
Hangzhou Gensciences Biopharmaceutical Co., Ltd.60 enrolled24 locationsNCT07663903
Recruiting
Phase 3
Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
Severe Hemophilia A
Hangzhou Gensciences Biopharmaceutical Co., Ltd.120 enrolled28 locationsNCT06142552